MCID: PRP019
MIFTS: 60

Peripheral Nervous System Disease

Categories: Neuronal diseases

Aliases & Classifications for Peripheral Nervous System Disease

MalaCards integrated aliases for Peripheral Nervous System Disease:

Name: Peripheral Nervous System Disease 12 15
Peripheral Neuropathy 12 76 54 29 6 73
Peripheral Nervous System Diseases 44
Peripheral Nerve Disorders 43
Peripheral Nerve Disease 12
Neuropathy, Peripheral 40

Classifications:



Summaries for Peripheral Nervous System Disease

NINDS : 54 Peripheral neuropathy describes damage to the peripheral nervous system, which transmits information from the brain and spinal cord to every other part of the body. More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms, pattern of development, and prognosis. Impaired function and symptoms depend on the type of nerves -- motor, sensory, or autonomic -- that are damaged.  Some people may experience temporary numbness, tingling, and pricking sensations, sensitivity to touch, or muscle weakness. Others may suffer more extreme symptoms, including burning pain (especially at night), muscle wasting, paralysis, or organ or gland dysfunction. Peripheral neuropathy may be either inherited or acquired. Causes of acquired peripheral neuropathy include physical injury (trauma) to a nerve, tumors, toxins, autoimmune responses, nutritional deficiencies, alcoholism, medical procedures, and vascular and metabolic disorders. Acquired peripheral neuropathies are caused by systemic disease, trauma from external agents, or infections or autoimmune disorders affecting nerve tissue. Inherited forms of peripheral neuropathy are caused by inborn mistakes in the genetic code or by new genetic mutations.

MalaCards based summary : Peripheral Nervous System Disease, also known as peripheral neuropathy, is related to motor peripheral neuropathy and sensory peripheral neuropathy, and has symptoms including back pain, headache and neuralgia. An important gene associated with Peripheral Nervous System Disease is IARS2 (Isoleucyl-TRNA Synthetase 2, Mitochondrial), and among its related pathways/superpathways are Neuroscience and Guidance Cues and Growth Cone Motility. The drugs Naproxen and Lidocaine have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, lung and brain, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A nervous system disease that affects the peripheral nervous system.

MedlinePlus : 43 Your peripheral nerves are the ones outside your brain and spinal cord. Like static on a telephone line, peripheral nerve disorders distort or interrupt the messages between the brain and the rest of the body. There are more than 100 kinds of peripheral nerve disorders. They can affect one nerve or many nerves. Some are the result of other diseases, like diabetic nerve problems. Others, like Guillain-Barre syndrome, happen after a virus infection. Still others are from nerve compression, like carpal tunnel syndrome or thoracic outlet syndrome. In some cases, like complex regional pain syndrome and brachial plexus injuries, the problem begins after an injury. Some people are born with peripheral nerve disorders. Symptoms often start gradually, and then get worse. They include Numbness Pain Burning or tingling Muscle weakness Sensitivity to touch Treatment aims to treat any underlying problem, reduce pain and control symptoms. NIH: National Institute of Neurological Disorders and Stroke

Wikipedia : 76 Peripheral neuropathy (PN) is damage to or disease affecting nerves, which may impair sensation,... more...

Related Diseases for Peripheral Nervous System Disease

Diseases related to Peripheral Nervous System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 101)
# Related Disease Score Top Affiliating Genes
1 motor peripheral neuropathy 34.4 GJB1 MFN2 MPZ PMP22
2 sensory peripheral neuropathy 33.9 GDAP1 GJB1 MAG MFN2 MPZ NGF
3 foot drop 32.7 MPZ PMP22
4 diabetic neuropathy 32.3 MPZ NGF PMP22 TRPV1
5 nervous system disease 30.8 AQP4 CD40LG MT-ND4 NGF TRPV1 TTR
6 axonal neuropathy 30.7 GDAP1 MFN2 PMP22
7 neuropathy 29.7 GDAP1 GJB1 MFN2 MPZ MT-ND4 NGF
8 peripheral neuropathy, myopathy, hoarseness, and hearing loss 12.4
9 agenesis of the corpus callosum with peripheral neuropathy 12.3
10 mental retardation, enteropathy, deafness, peripheral neuropathy, ichthyosis, and keratoderma 12.3
11 optic atrophy, hearing loss, and peripheral neuropathy, autosomal recessive 12.2
12 cervical hypertrichosis peripheral neuropathy 12.1
13 autonomic peripheral neuropathy 12.1
14 motor neuropathy, peripheral, with dysautonomia 12.0
15 deafness, sensorineural, with peripheral neuropathy and arterial disease 11.9
16 optic atrophy, hearing loss, and peripheral neuropathy, autosomal dominant 11.9
17 spinocerebellar ataxia with rigidity and peripheral neuropathy 11.9
18 peripheral neuropathy, ataxia, focal necrotizing encephalopathy, and spongy degeneration of brain 11.9
19 deafness peripheral neuropathy arterial disease 11.9
20 autosomal dominant optic atrophy and peripheral neuropathy 11.9
21 non-progressive predominantly posterior cavitating leukoencephalopathy with peripheral neuropathy 11.9
22 hereditary neuropathy with liability to pressure palsy 11.1 MPZ PMP22
23 congenital hypomyelination neuropathy 11.1 MPZ PMP22
24 charcot-marie-tooth disease, demyelinating, type 1c 11.1 MPZ NEFL PMP22
25 mononeuritis of lower limb 11.1 PMP22 TRPV1
26 roussy-levy hereditary areflexic dystasia 11.0 MPZ PMP22
27 charcot-marie-tooth neuropathy type 1 11.0 GJB1 MPZ PMP22
28 charcot-marie-tooth disease, demyelinating, type 1b 11.0 GJB1 MPZ PMP22
29 charcot-marie-tooth disease, axonal, type 2b 11.0 GJB1 MPZ PMP22
30 nerve compression syndrome 11.0 PMP22 PSMD9 TTR
31 charcot-marie-tooth disease, demyelinating, type 1d 11.0 GJB1 MPZ PMP22
32 charcot-marie-tooth disease, x-linked dominant, 1 11.0 GDAP1 GJB1 MPZ
33 lesion of sciatic nerve 11.0 NGF TRPV1
34 polyradiculoneuropathy 11.0 MAG MPZ PMP22
35 autoimmune disease of central nervous system 11.0 CD40LG MAG
36 carpal tunnel syndrome 11.0 PMP22 PSMD9 TTR
37 amyloid tumor 11.0 MYOM2 TTR TUBB3
38 amyotrophic neuralgia 11.0 GJB1 PMP22
39 pelizaeus-merzbacher disease 10.9 MAG MPZ PMP22
40 mononeuritis multiplex 10.9 CD40LG MAG
41 charcot-marie-tooth disease, demyelinating, type 1f 10.9 GJB1 MPZ NEFL PMP22
42 guillain-barre syndrome 10.9 CD40LG MPZ PMP22
43 mononeuritis of upper limb and mononeuritis multiplex 10.9 CD40LG MAG MYOM2
44 hypersensitivity reaction disease 10.9 CD40LG MUSK TRPV1
45 acquired metabolic disease 10.9 PSMD9 TRPV1 TTR
46 chronic polyneuropathy 10.9 CD40LG MAG MYOM2
47 charcot-marie-tooth disease, axonal, type 2f 10.9 GJB1 MPZ
48 sciatic neuropathy 10.9 MYOM2 NGF TRPV1
49 charcot-marie-tooth disease, axonal, type 2k 10.9 GDAP1 MFN2 TUBB3
50 miller fisher syndrome 10.9 CD40LG MAG

Graphical network of the top 20 diseases related to Peripheral Nervous System Disease:



Diseases related to Peripheral Nervous System Disease

Symptoms & Phenotypes for Peripheral Nervous System Disease

UMLS symptoms related to Peripheral Nervous System Disease:


back pain, headache, neuralgia, pain, sciatica, seizures, syncope, tremor, chronic pain, atypical facial pain, neurologic symptoms, vertigo/dizziness, sleeplessness, hemiparesis

GenomeRNAi Phenotypes related to Peripheral Nervous System Disease according to GeneCards Suite gene sharing:

26 (show all 30)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.84 IARS2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.84 IARS2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.84 PSMD9
4 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.84 PSMD9 IARS2 MUSK NEFL
5 Increased shRNA abundance (Z-score > 2) GR00366-A-129 9.84 PSMD9
6 Increased shRNA abundance (Z-score > 2) GR00366-A-13 9.84 NEFL
7 Increased shRNA abundance (Z-score > 2) GR00366-A-140 9.84 NEFL
8 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.84 IARS2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.84 PSMD9
10 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.84 MUSK
11 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.84 PSMD9
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.84 NEFL
13 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.84 NEFL
14 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.84 NEFL
15 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.84 MUSK
16 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.84 MUSK
17 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.84 IARS2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.84 NEFL
19 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.84 MUSK
20 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.84 PSMD9
21 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.84 MUSK
22 Increased shRNA abundance (Z-score > 2) GR00366-A-5 9.84 NEFL
23 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.84 PSMD9
24 Increased shRNA abundance (Z-score > 2) GR00366-A-51 9.84 PSMD9
25 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.84 IARS2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.84 MUSK
27 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.84 MUSK
28 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.84 PSMD9
29 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.84 MUSK
30 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.84 IARS2

MGI Mouse Phenotypes related to Peripheral Nervous System Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.07 PHOX2B PMP22 PNPLA6 TRPV1 AQP4 GDAP1
2 cellular MP:0005384 9.9 TUBB3 CD40LG GDAP1 GJB1 MFN2 MPZ
3 homeostasis/metabolism MP:0005376 9.8 AQP4 CD40LG GDAP1 GJB1 MAG MFN2
4 nervous system MP:0003631 9.5 AQP4 CD40LG GDAP1 GJB1 MAG MFN2

Drugs & Therapeutics for Peripheral Nervous System Disease

Drugs for Peripheral Nervous System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 816)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Naproxen Approved, Vet_approved Phase 4,Phase 2 22204-53-1 1302 156391
2
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
3
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1 174722-31-7 10201696
4
Remifentanil Approved Phase 4,Phase 3,Not Applicable 132875-61-7 60815
5
Imipramine Approved Phase 4 50-49-7 3696
6
Etoricoxib Approved, Investigational Phase 4,Phase 2 202409-33-4 123619
7
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2180-92-9, 38396-39-3 2474
8
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
9
Hydroxocobalamin Approved Phase 4,Phase 3,Phase 2,Not Applicable 13422-51-0 11953898 44475014
10
Minocycline Approved, Investigational Phase 4,Phase 2,Not Applicable 10118-90-8 5281021
11
Acetylcholine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-84-3 187
12
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 27203-92-5 33741
13
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-41-2 439260
14
Carbamazepine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 298-46-4 2554
15
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 6740-88-1 3821
16
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 60142-96-3 3446
17
Amitriptyline Approved Phase 4,Phase 3,Phase 2,Not Applicable 50-48-6 2160
18
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-27-2 5288826
19
Fexofenadine Approved, Investigational Phase 4 83799-24-0 3348
20
Capsaicin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 404-86-4 1548943
21
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 148553-50-8 5486971
22
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
23
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 124-94-7 31307
24
Naloxone Approved, Vet_approved Phase 4,Phase 2 465-65-6 5284596
25
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 76-42-6 5284603
26
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-24-8 5755
27
Stavudine Approved, Investigational Phase 4,Phase 3 3056-17-5 18283
28
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Not Applicable 103-90-2 1983
29
Ropivacaine Approved Phase 4,Phase 3,Phase 2,Not Applicable 84057-95-4 71273 175805
30
Ibuprofen Approved Phase 4,Phase 2,Phase 3,Not Applicable 15687-27-1 3672
31
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
32
Perphenazine Approved Phase 4,Phase 3,Phase 2,Not Applicable 58-39-9 4748
33
Histamine Approved, Investigational Phase 4,Phase 2,Not Applicable 75614-87-8, 51-45-6 774
34
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 179324-69-7 387447 93860
35
Nabilone Approved, Investigational Phase 4,Phase 3,Phase 2 51022-71-0 5284592
36
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
37
Oxcarbazepine Approved Phase 4,Not Applicable 28721-07-5 34312
38
Ethanol Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 64-17-5 702
39
Epinephrine Approved, Vet_approved Phase 4,Not Applicable 51-43-4 5816
40
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 83-43-2 6741
41
Dronabinol Approved, Illicit Phase 4,Phase 3,Phase 2 1972-08-3 16078
42
Levobupivacaine Approved, Investigational Phase 4,Phase 3,Not Applicable 27262-47-1 92253
43
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
44
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
45
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56-12-2 119
46
Racepinephrine Approved Phase 4,Not Applicable 329-65-7 838
47
Mexiletine Approved, Investigational Phase 4,Phase 3,Phase 2 31828-71-4 4178
48
Isoniazid Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 54-85-3 3767
49
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
50
Quinapril Approved, Investigational Phase 4 85441-61-8 54892

Interventional clinical trials:

(show top 50) (show all 2434)
# Name Status NCT ID Phase Drugs
1 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy Unknown status NCT00123136 Phase 4
2 The Impact of Perioperative Gabapentin on Chronic Groin Pain After Inguinal Hernia Repair Unknown status NCT02419443 Phase 4 Gabapentin;Placebo
3 Evaluation of Viral Efficacy and Safety of a Reduced Dose of Stavudine (d4T): THE PHOENIX STUDY Unknown status NCT00235222 Phase 4 stavudine
4 Pregabalin for the Treatment of Uremic Pruritus Unknown status NCT01852318 Phase 4 pregabalin 75mg daily for 12 weeks;fexofenadine 60 mg daily for 12 weeks;placebo
5 A Post-marketing Evaluation of a Compound Traditional Chinese Herbal Medicine, Qishe Pill, on Cervical Radiculopathy Unknown status NCT01875562 Phase 4 Qishe Pill
6 Imipramine and Pregabalin Combination in Painful Polyneuropathy Unknown status NCT01047488 Phase 4 Imipramine;Pregabalin;Imipramine, pregabalin;Placebo
7 Determination of the Antidepressant Duloxetine in Plasma to Improve the Knowledge of the Analgesic Action of Antidepressants on Chronic Neuropathic Pain Unknown status NCT02846701 Phase 4 duloxetine
8 Evaluation of the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Neuropathic Pain Unknown status NCT01264237 Phase 4 Etoricoxib;Placebo
9 Duration of Antibiotic Therapy in Community - Acquired Pneumonia Unknown status NCT01492387 Phase 4
10 Conservative Versus Aggressive Discectomy for Primary Disc Herniation With Radiculopathy Unknown status NCT01204008 Phase 4
11 Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences. Unknown status NCT02033057 Phase 4
12 Preventing Pain After Heart Surgery Unknown status NCT01480765 Phase 4 Pregabalin;Ketamine infusion;Placebo capsules;Placebo infusion
13 Comparison of Intravenous Ibuprofen and Paracetamol in Patients With Sciatica Presented to the Emergency Department Unknown status NCT02777320 Phase 4 paracetamol;Ibuprofen
14 IV Paracetamol vs IV Morphine vs Placebo in Sciatalgia Unknown status NCT02504996 Phase 4 Paracetamol;morphine;Placebo
15 Qutenza for Critical Ischaemia in End Stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
16 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Unknown status NCT01838174 Phase 4 ACTHAR Gel (ACTH);IV steroids with oral taper
17 Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy Unknown status NCT01770964 Phase 4 Pregabalin;placebo
18 Pregabalin for the Treatment and Prevention of Spinal Cord Injury Neuropathic Pain Unknown status NCT01479556 Phase 4 Pregabalin;Placebo
19 Effects of Pregabalin on Mechanical Hyperalgesia Unknown status NCT00310583 Phase 4 Pregabalin
20 Inspiratory Muscle Training in Patients With Autonomic Neuropathic Unknown status NCT00752440 Phase 4
21 Safety and Efficacy of Mecobalamin Injection in Peripheral Neuropathies Patients (Study JGAZSY091109) Completed NCT01192113 Phase 4 Mecobalamin IV Injection;Mecobalamin IM injection;Mecobalamin IV or IM injection
22 A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN) Completed NCT01675531 Phase 4 Targin
23 Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
24 Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy Completed NCT00159731 Phase 4 Pregabalin
25 Efficacy of Administration of ACE-Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus Completed NCT03031834 Phase 4 Quinapril
26 Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Diabetic Peripheral Neuropathy Completed NCT00380913 Phase 4 Cesamet™ (nabilone)
27 Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy Completed NCT00159679 Phase 4 Pregabalin
28 A Study To Evaluate Pregabalin In Patients With Painful Diabetic Peripheral Neuropathy (DPN) Completed NCT00156078 Phase 4 pregabalin
29 A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Completed NCT00629681 Phase 4 Pregabalin
30 Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in Diabetic Peripheral Neuropathy Pain Management Completed NCT01364298 Phase 4 Gabapentin/B-complex;Pregabalin
31 Intrathecal Bolus Doses of Ziconotide Completed NCT01373983 Phase 4 Ziconotide
32 Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP Completed NCT00407511 Phase 4 Pregabalin
33 Comparison of the Analgesic Effect of Different Local Anesthetics in Interscalene Nerve Block for Shoulder Surgery Completed NCT02691442 Phase 4 Ropivacaine 0.75%;Levobupivacaine 0.5%;Levobupivacaine 0.5% + epinephrin 1/200000
34 Effect of Pulsing Electrical Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
35 Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy Completed NCT00380965 Phase 4 Cesamet™ (nabilone)
36 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
37 Frequency Modulated Neural Stimulation (FREMS) in Symptomatic Diabetic Neuropathy Completed NCT01628627 Phase 4
38 A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
39 A Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy Completed NCT00573261 Phase 4 Pregabalin;Placebo
40 Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines Completed NCT01076478 Phase 4 Cilostazol
41 Comparison of the Efficacy of Duloxetine With Placebo in Patients With Chronic Low Back Pain With a Radicular Component Completed NCT01166048 Phase 4 Duloxetine;Duloxetine
42 An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus) Completed NCT00194909 Phase 4 sildenafil (Viagra)
43 Effect of Arginine on Microcirculation in Patients With Diabetes Completed NCT00902616 Phase 4
44 The Effect of α-lipoic Acid Treatment in Patient With Cardiac Autonomic Neuropathy Completed NCT02056366 Phase 4 α-lipoic acid
45 A Study to Compare Safety and Efficacy of Tramadol Hydrochloride/Acetaminophen With Gabapentin in Participants With Diabetic Neuropathy Completed NCT00634543 Phase 4 Tramadol hydrochloride/ Acetaminophen;Gabapentin
46 Pharmacokinetics and Optimal Timing of Dronedarone Initiation Following Long-term Amiodarone in Patients With Paroxysmal or Persistent Atrial Fibrillation Completed NCT01199081 Phase 4 Dronedarone
47 CHLOROQUINE FOR MAINTENANCE REMISSION OF AUTOIMMUNE HEPATITIS Completed NCT01980745 Phase 4 Chloroquine diphosphate 250mg;Placebo
48 Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations Completed NCT02260388 Phase 4 Nortriptyline;Duloxetine;Pregabalin;Mexiletine
49 Desensitization in Kidney Transplantation Completed NCT00908583 Phase 4 plasmapheresis;Bortezomib;Rituximab;Methylprednisolone
50 Escitalopram as a Treatment for Pain in Polyneuropathy Completed NCT00162968 Phase 4 escitalopram

Search NIH Clinical Center for Peripheral Nervous System Disease

Cochrane evidence based reviews: peripheral nervous system diseases

Genetic Tests for Peripheral Nervous System Disease

Genetic tests related to Peripheral Nervous System Disease:

# Genetic test Affiliating Genes
1 Peripheral Neuropathy 29

Anatomical Context for Peripheral Nervous System Disease

MalaCards organs/tissues related to Peripheral Nervous System Disease:

41
Spinal Cord, Lung, Brain, Testes, Cortex, Bone, Skin

Publications for Peripheral Nervous System Disease

Articles related to Peripheral Nervous System Disease:

(show top 50) (show all 1151)
# Title Authors Year
1
Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30. ( 28954297 )
2018
2
Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review. ( 28954296 )
2018
3
Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort. ( 29439162 )
2018
4
Synthetic peripherally-restricted cannabinoid suppresses chemotherapy-induced peripheral neuropathy pain symptoms by CB1 receptor activation. ( 29981335 )
2018
5
[EXPRESS] TRPA1 sensitization during diabetic vascular impairment contributes to cold hypersensitivity in a mouse model of painful diabetic peripheral neuropathy. ( 29968518 )
2018
6
Correlation between serum vitamin B12 level and peripheral neuropathy in atrophic gastritis. ( 29599609 )
2018
7
Identification of IFRD1 variant in a Han Chinese family with autosomal dominant hereditary spastic paraplegia associated with peripheral neuropathy and ataxia. ( 29362493 )
2018
8
Effect of diverse physical rehabilitative interventions on static postural control in diabetic peripheral neuropathy: a systematic review. ( 29979897 )
2018
9
Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia. ( 29963528 )
2018
10
AAVrh10 gene therapy ameliorates central and peripheral nervous system disease in canine globoid cell leukodystrophy (Krabbe disease). ( 29316812 )
2018
11
Ergothioneine ameliorates oxaliplatin-induced peripheral neuropathy in rats. ( 29981320 )
2018
12
Fasudil combined with methylcobalamin or lipoic acid can improve the nerve conduction velocity in patients with diabetic peripheral neuropathy: A meta-analysis. ( 29979431 )
2018
13
Peripheral neuropathy in Tangier disease: A literature review and assessment. ( 29582519 )
2018
14
The Peripheral Neuropathies of POEMS Syndrome and Castleman Disease. ( 29157616 )
2018
15
Evoked and Ongoing Pain-Like Behaviours in a Rat Model of Paclitaxel-Induced Peripheral Neuropathy. ( 29973969 )
2018
16
Kikuchi's disease (histiocytic necrotizing lymphadenitis): A rare presentation with acute kidney injury, peripheral neuropathy, and aseptic meningitis with cutaneous involvement. ( 29567898 )
2018
17
Peripheral neuropathies: Antisense therapy for Charcot-Marie-Tooth disease? ( 29269786 )
2018
18
Substrate interaction defects in histidyl-tRNA synthetase linked to dominant axonal peripheral neuropathy. ( 29235198 )
2018
19
Clinical Characteristics and Treatment Response of Peripheral Neuropathy in the Presence of Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Experience at a Single Tertiary Center. ( 28079316 )
2017
20
Peripheral Neuropathy Due to Recreational Use of Nitrous Oxide Presenting After an Ankle Sprain With Foot Drop. ( 29120005 )
2017
21
Association of aldose reductase gene polymorphism (C-106T) in susceptibility of diabetic peripheral neuropathy among north Indian population. ( 28495421 )
2017
22
An experimental model of the "dual diagnosis": Effect of cytotoxic brain edema plus peripheral neuropathy on the spontaneous locomotor activity of rats. ( 29298281 )
2017
23
Type 1 diabetic patients with peripheral neuropathy have pan-enteric prolongation of gastrointestinal transit times and an altered caecal pH profile. ( 28105520 )
2017
24
Paget's Disease of Bone Presenting with Peripheral Neuropathy. ( 29279507 )
2017
25
Plantar fascia enthesopathy is highly prevalent in diabetic patients without peripheral neuropathy and correlates with retinopathy and impaired kidney function. ( 28358891 )
2017
26
Peripheral neuropathy in limbic encephalitis with anti-glutamate receptor antibodies: Case report and systematic literature review. ( 28948076 )
2017
27
Perspectives on Peripheral Neuropathy as a Consequence of Metformin-Induced Vitamin B12 Deficiency in T2DM. ( 28932240 )
2017
28
Serum folate, vitamin B12 levels and diabetic peripheral neuropathy in type 2 diabetes: A meta-analysis. ( 28081987 )
2017
29
POEMS syndrome: a rare cause of exudative ascites and chronic peripheral neuropathy. ( 28637843 )
2017
30
Investigation of the vitamin B12 deficiency with peripheral neuropathy in patients with type 2 diabetes mellitus treated using metformin. ( 29270571 )
2017
31
Anti-allodynic effect of Buja in a rat model of oxaliplatin-induced peripheral neuropathy via spinal astrocytes and pro-inflammatory cytokines suppression. ( 28088201 )
2017
32
Homozygous mutation in PTRH2 gene causes progressive sensorineural deafness and peripheral neuropathy. ( 28328138 )
2017
33
The relationship between neutrophil-to-lymphocyte ratio and diabetic peripheral neuropathy in Type 2 diabetes mellitus. ( 29137012 )
2017
34
Peripheral Neuropathy and Nerve Compression Syndromes in Burns. ( 28888304 )
2017
35
High Prevalence and Incidence of Diabetic Peripheral Neuropathy in Children and Adolescents With Type 1 Diabetes Mellitus: Results From a Five-Year Prospective Cohort Study. ( 29429781 )
2017
36
Association of apolipoprotein-CIII (apoC-III), endothelium-dependent vasodilation and peripheral neuropathy in a multi-ethnic population with type 2 diabetes. ( 28641786 )
2017
37
Alternative stable conformation capable of protein misinteraction links tRNA synthetase to peripheral neuropathy. ( 28531329 )
2017
38
Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese. ( 28447211 )
2017
39
Dose-response of pregabalin for diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia. ( 28967801 )
2017
40
Association Between Tumor Necrosis Factor-I+ and Diabetic Peripheral Neuropathy in Patients with Type 2 Diabetes: a Meta-Analysis. ( 26797519 )
2017
41
Nicotinamide riboside, a form of vitamin B3 and NAD+ precursor, relieves the nociceptive and aversive dimensions of paclitaxel-induced peripheral neuropathy in female rats. ( 28346814 )
2017
42
Subacute demyelinating peripheral neuropathy as a novel presentation of late infantile metachromatic leukodystrophy. ( 28667691 )
2017
43
Effects of Common Polymorphisms in the MTHFR and ACE Genes on Diabetic Peripheral Neuropathy Progression: a Meta-Analysis. ( 26971290 )
2017
44
TNF-Alpha in Peripheral Neuropathy Patients with Impaired Glucose Regulation. ( 28251164 )
2017
45
A critical appraisal of the mild axonal peripheral neuropathy of late neurologic Lyme disease. ( 27914746 )
2017
46
Genetic Prion Disease Caused by PRNP Q160X Mutation Presenting with an Orbitofrontal Syndrome, Cyclic Diarrhea, and Peripheral Neuropathy. ( 27716661 )
2017
47
Spontaneous pain is reduced by conditioning pain modulation in peripheral neuropathy but not in fibromyalgia-Implications for different pain mechanisms. ( 29913839 )
2017
48
Dog bites and diabetic peripheral neuropathy: a dangerous combination. ( 28942411 )
2017
49
Aberrant microRNA expression in patients with painful peripheral neuropathies. ( 28870579 )
2017
50
Peripheral Neuropathy, Episodic Rhabdomyolysis, and Hypoparathyroidism in a Patient with Mitochondrial Trifunctional Protein Deficiency. ( 28685493 )
2017